Mark Mascolini

Mark Mascolini has been writing about HIV and AIDS since the beginning of the epidemic. Peer-reviewed work he coauthored has appeared in JAIDS, Antiviral Therapy and the Journal of the International AIDS Society.

His work appears regularly on TheBodyPRO.com and the websites of the National AIDS Treatment Advocacy Project (NATAP), AVAC and the Center for AIDS, as well as in Reviews in Antiviral Therapy & Infectious Diseases.

Mascolini has published interviews with scores of leading HIV investigators, including Bernard Branson, Myron Cohen, Kevin DeCock, Anthony Fauci, Robert Grant, David Ho, Daniel Kuritzkes, Joep Lange and Mark Wainberg.

Categories Covered:HIV Prevention Methods, Maraviroc (Selzentry, Celsentri), HIV Epidemiology, Adverse Events, Comorbidities, and HIV, HIV Treatments in Development, HIV Treatment Strategies, PrEP (HIV Pre-Exposure Prophylaxis), Providing Quality HIV Care, Managing Long-Term HIV Survivors, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (Atripla), Cobicistat/Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate (Stribild), HIV Care Continuum, HIV and Mental Health Care, Switching or Stopping HIV Treatment, U=U (Undetectable Equals Untransmittable, i.e. HIV Treatment as Prevention), Managing People Newly Diagnosed With HIV, HIV, Discrimination, and Law, FDA-Approved HIV Medications, First-Line HIV Treatment, HIV Education and Risk Management, Dolutegravir (Tivicay), Managing HIV Drug Resistance, HIV Care and Services Outside the US, Meeting the Costs of HIV Care, Abacavir/Dolutegravir/Lamivudine (Triumeq), HIV Testing, Atazanavir (Reyataz), Pregnancy, Childbirth, and HIV, Etravirine (Intelence), Rilpivirine (Edurant), Tenofovir Disoproxil Fumarate (Viread), Pediatric HIV Care, Lopinavir/Ritonavir (Kaletra), Cobicistat/Emtricitabine/Elvitegravir/Tenofovir Alafenamide (Genvoya, E/C/F/TAF), Managing Primary/Acute HIV Infection, HIV Case Management and Social Work, HIV Basic Science and Pathogenesis, Primary Care of People With HIV, Raltegravir (Isentress), HIV Policy and Advocacy

Latest by Mark Mascolini

Alcohol and HIV: When to Screen, What to Say, How to Treat

An interview with Jeffrey Samet, M.D., M.A., M.P.H., an international authority on addiction medicine with a special interest in addictions among people with HIV infection.

By Mark Mascolini for The Center for AIDS Information & Advocacy

Big 3 Lung Cancer Risk Factors With HIV: Smoking, Low CD4s, Lung Infection

Smoking so dominates the lung cancer risk list that other factors struggle for a small slice of the spotlight.

By Mark Mascolini for The Center for AIDS Information & Advocacy

Lung Cancer Risk and Screening With HIV -- and an Intriguing New Treatment Opportunity

Highly regarded for his contributions to cancer research in people with HIV, Keith M. Sigel, M.D., Ph.D., M.P.H., has led numerous innovative studies on these conditions and others in people with HIV.

By Mark Mascolini for The Center for AIDS Information & Advocacy

Asymptomatic STIs Frequently Occur Among People With Primary HIV Infection

Researchers conclude that tri-monthly STI screening including asymptomatic individuals should be considered for people with primary HIV infection, particularly in men who have sex with men who report sexual risk behavior.

By Mark Mascolini

Immediate HIV Treatment Has Little Impact on Risk of Future Drug Resistance

Starting antiretroviral therapy immediately rather waiting until a person's CD4 count falls below 500 cells/µL has almost no impact on the person's risk of developing antiretroviral resistance over the next seven years, according to recent research....

By Mark Mascolini

HIV Independently Tied to Airway Obstruction in Smokers 40 or Older

HIV infection increased the risk of airway obstruction within a 1,053-person study of cigarette smokers in France, according to findings published online in the journal AIDS.

By Mark Mascolini

Marijuana May Quell HIV-Related Neuroinflammation via CD16 Expression

A small study has found that HIV-positive men who used marijuana had fewer markers for HIV-associated inflammation than HIV-positive men who did not.

By Mark Mascolini

HIV Rate in U.S. Falls Between 2011 and 2016, While Prevalence Climbs

HIV incidence fell about 9% overall in a five-year span, the CDC found, but it rose in some groups, including people 25 to 29 years old, Asians, and American Indians.

By Mark Mascolini

Late 2017 HIV Conferences Focus on Antiretrovirals and Comorbidities

2017 may be winding down, but even as the year wanes, we’ve seen significant new HIV research featured in major scientific conferences in the U.S. and Europe. IDWeek, most recently held in San Diego in early October 2017, is an annual infectious disease...

By Mark Mascolini

Weight Gain When Switching From Efavirenz to an Integrase Inhibitor

Virally suppressed people who swapped an efavirenz regimen for one based on an integrase inhibitor gained significantly more weight over 18 months than those who stayed with efavirenz or switched to a protease inhibitor.

By Mark Mascolini